The collaboration, which will involve biological development work aimed at progressing Organon’s program for the identification of more selective steroid hormone receptor modulators, will initially last for a period of two years.
Shanghai Genomics, which in 2005 merged with GNI Ltd., the Asia-based global pharmaceutical company, will use its expertise in protein purification and cell-based interaction assays to clarify the clinical relevance of a number of receptor interacting proteins and their use in drug discovery.
In particular, the research will focus upon the areas of rheumatoid arthritis, atherosclerosis and oncology.
"We are delighted to have successfully finalized this new research partnership with Shanghai Genomics as part of our research strategy to forge closer links with China’s highly skilled and motivated scientists," said Dr David Nicholson, Executive Vice President Global Research, Organon International Inc.
"This is now the second major research collaboration deal that Organon has recently finalized in China."
"We are confident that Shanghai Genomics’ integrated drug discovery platform and their expertise in nuclear receptor biology will result in a successful project, in close collaboration with our own research scientists," he added.
Ying Luo, President and CEO Shanghai Genomics, and President and COO of GNI said, "Shanghai Genomics is delighted to be collaborating with Organon on this exciting project."
"This is yet another validation of the model we have refined with GNI, where we are the first and the only company to combine innovative Western science with cost-efficient research capabilities in China, and access to the Chinese and Japanese pharmaceutical markets."
"Utilizing our highly efficient yet cost-effective technology platform we have entered into and completed numerous research based collaborations with international partners such as Organon, and we look forward to furthering our research efforts in these important areas."